GOLDMAN SACHS GROUP INC - MEREO BIOPHARMA GROUP PLC ownership

MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 56 filers reported holding MEREO BIOPHARMA GROUP PLC in Q2 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of MEREO BIOPHARMA GROUP PLC
ValueSharesWeighting
Q3 2023$2,610,537
-0.2%
2,023,672
+2.1%
0.00%0.0%
Q2 2023$2,616,776
+63.6%
1,982,406
-12.4%
0.00%
Q1 2023$1,599,563
-7.1%
2,262,785
-1.4%
0.00%
Q4 2022$1,721,075
+181.7%
2,294,766
+223.6%
0.00%
Q3 2022$611,000
-24.0%
709,126
-1.2%
0.00%
Q2 2022$804,000
+0.4%
717,455
+0.3%
0.00%
Q1 2022$801,000
-29.7%
715,185
+0.4%
0.00%
Q4 2021$1,140,000712,3630.00%
Other shareholders
MEREO BIOPHARMA GROUP PLC shareholders Q2 2023
NameSharesValueWeighting ↓
Tejara Capital Ltd 2,188,606$1,641,4550.95%
Monaco Asset Management SAM 2,049,661$1,537,2460.46%
Rubric Capital Management LP 10,366,120$7,774,5900.34%
Clearline Capital LP 2,052,709$1,539,5320.28%
DAFNA Capital Management LLC 1,096,513$822,3850.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 7,364,438$5,523,3290.23%
Orbimed Advisors 10,605,522$7,954,1420.15%
Octagon Capital Advisors LP 1,000,000$750,0000.12%
Rock Springs Capital Management LP 6,244,897$4,683,6730.11%
Privium Fund Management (UK) Ltd 177,200$132,9000.10%
View complete list of MEREO BIOPHARMA GROUP PLC shareholders